We are live on ! Find out more
FHTX icon

Foghorn Therapeutics
FHTX

60 hedge funds and large institutions have $357M invested in Foghorn Therapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 14

3.24% more ownership

Funds ownership: 60.13% → 63.36% (+3.2%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 12

2% less funds holding

Funds holding: 61 → 60 (-1)

6% less capital invested

Capital invested by funds: $379M → $357M (-$21.7M)

Holders
60
Holders Change
-1
Holders Change %
-1.64%
% of All Funds
1.01%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
12
Increased
20
Reduced
14
Closed
12
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
+$195K

Top Buyers

1
DM
Deerfield Management
New York
+$6.95M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.79M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.07M
4
Morgan Stanley
Morgan Stanley
New York
+$2.49M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.89M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$892K
2
KCM
Kingdon Capital Management
New York
-$826K
3
N
Nuveen
North Carolina
-$687K
4
BlackRock
BlackRock
New York
-$425K
5
State of Wisconsin Investment Board
State of Wisconsin Investment Board
Wisconsin
-$396K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAL
51
Capital Analysts LLC
Pennsylvania
$8K – – –
Osaic Holdings
52
Osaic Holdings
Arizona
$4K – – –
CSS
53
Cubist Systematic Strategies
Connecticut
$3K -$115K -8,944 -98%
PHK
54
Point72 Hong Kong
Hong Kong
$3K +$2.62K +203 New
LC
55
Lindbrook Capital
California
$2K +$1.68K +130 New
S
56
SignatureFD
Georgia
$1K -$1.79K -139 -76%
Citadel Advisors
57
Citadel Advisors
Florida
– -$892K -58,546 Closed
KCM
58
Kingdon Capital Management
New York
– -$826K -54,241 Closed
State of Wisconsin Investment Board
59
State of Wisconsin Investment Board
Wisconsin
– -$396K -26,000 Closed
JGC
60
J. Goldman & Co
New York
– -$388K -25,488 Closed
D.E. Shaw & Co
61
D.E. Shaw & Co
New York
– -$302K -19,855 Closed
Dimensional Fund Advisors
62
Dimensional Fund Advisors
Texas
– -$300K -19,758 Closed
UBS Group
63
UBS Group
Switzerland
– -$45K -2,923 Closed
CG
64
Cutler Group
California
– -$9K -600 Closed
HNWAG
65
High Net Worth Advisory Group
Florida
– -$8K -500 Closed
CAPTRUST Financial Advisors
66
CAPTRUST Financial Advisors
North Carolina
– -$2K -100 Closed
GWS
67
Glassman Wealth Services
Virginia
– -$1K -53 Closed
Simplex Trading
68
Simplex Trading
Illinois
– -$542 -42 Closed
SOW
69
State of Wyoming
Wyoming
– +$13 +1 +33%
US Bancorp
70
US Bancorp
Minnesota
– +$39 +3 New
CS
71
Credit Suisse
Switzerland
– +$258 +20 New
EI
72
Ellevest Inc
New York
– +$271 +21 New
1 2
3

FHTX Hedge Fund Activity: Q2 2022 in Review

60 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q2 2022, worth a combined $357M — down 5.7% from $379M a quarter earlier.

Fund positioning in FHTX was balanced in Q2 2022: 12 funds opened new positions, 12 closed out, 20 added to existing stakes and 14 trimmed.

The largest buyer was Deerfield Management, adding an estimated $6.95M. The largest seller was Citadel Advisors, exiting entirely with an estimated $892K sold.

  • 60 institutional investors held Foghorn Therapeutics (FHTX) as of Q2 2022, down from 61 in Q1 2022.
  • Funds reported $357M of Foghorn Therapeutics stock for Q2 2022, down 5.7% quarter-over-quarter.
  • 12 funds opened new Foghorn Therapeutics positions in Q2 2022 and 12 closed out, a net change of 0 holders.
  • The largest Foghorn Therapeutics buyer in Q2 2022 was Deerfield Management, an estimated $6.95M added.
  • The largest Foghorn Therapeutics seller in Q2 2022 was Citadel Advisors, an estimated $892K sold.

Based on aggregated 13F filings for Q2 2022.